Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v3.20.2
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Consolidated Statements of Operations and Comprehensive Loss    
Revenues $ 1,638 $ 2,018
Operating expenses:    
Research and development (related party of $97 and $954), net of grant income of $0 and $37 3,213 5,474
General and administrative (related party of $1,143 and $1,051) 12,428 12,332
Total operating expenses 15,641 17,806
Operating loss (14,003) (15,788)
Other income (expense):    
Interest expense - related party (2,466) (1,900)
Interest income 15 75
Royalty income 10 16
Total other income (expense) (2,441) (1,809)
Consolidated net loss (16,444) (17,597)
Net loss attributable to noncontrolling interest 5 4
Net loss attributable to iBio, Inc. (16,439) (17,593)
Deemed dividends - down round of Series A Preferred and Series B Preferred (21,560) 0
Preferred stock dividends - iBio CMO Preferred Tracking Stock (261) (260)
Net loss available to iBio, Inc. (38,260) (17,853)
Comprehensive loss:    
Consolidated net loss (16,444) (17,597)
Other comprehensive loss - foreign currency translation adjustments (2) (1)
Comprehensive loss $ (16,446) $ (17,598)
Loss per common share attributable to iBio, Inc. stockholders - basic and diluted $ (0.61) $ (0.94)
Weighted-average common shares outstanding - basic and diluted 62,795 18,926